Sunlenca (Lenacapavir Injection 463.5 mg/1.5 ml)

Sunlenca (Lenacapavir Injection 463.5 mg/1.5 ml) – Gilead Sciences

Description:
Sunlenca (Lenacapavir) is a groundbreaking long-acting HIV-1 capsid inhibitor developed by Gilead Sciences. It is designed for the treatment of multi-drug-resistant HIV-1 infection in adults who have limited treatment options due to resistance, intolerance, or safety concerns with other antiretroviral drugs.

Administered as a subcutaneous injection every six months, Sunlenca provides durable viral suppression with just two doses per year, offering unmatched convenience and adherence for patients with chronic HIV infection.

Dosage Form:

• Injectable solution – 463.5 mg/1.5 ml (309 mg/ml)
• Administered subcutaneously by a qualified healthcare professional.
• Maintenance dose: 927 mg every 6 months following the loading phase.

Mechanism of Action:
Lenacapavir targets the HIV-1 capsid protein, a critical structural component of the virus. By disrupting multiple stages of the viral lifecycle — including capsid assembly, nuclear import, and viral replication — it prevents HIV from multiplying and spreading in the body.

Key Benefits:

• First-in-class long-acting capsid inhibitor
• Only twice-yearly injection for sustained viral suppression
• Effective in patients with multi-drug-resistant HIV-1
• Reduces dependence on daily oral therapy